UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

SCHEDULE 14a

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(                               )

  

Filed by the Registrant   ☒ Filed by a Party other than the Registrant   ☐

  

Check the appropriate box:

  

Preliminary Proxy Statement.
   
Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)).
   
Definitive Proxy Statement.
   
Definitive Additional Materials.
   
Soliciting Material Pursuant to § 240.14a-12.

 

 

NATUS MEDICAL INCORPORATED
(Name of Registrant as Specified in its Charter)

 

 
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of filing fee (Check the appropriate box):

 

No fee required.
   
☐  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

  (1) Title of each class of securities to which transaction applies:
     
  (2) Aggregate number of securities to which the transaction applies:
     
  (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
     
  (4) Proposed maximum aggregate value of transaction:
     
  (5) Total fee paid:

   
☐  Fee paid previously with preliminary materials.
   
☐  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

  (1) Amount previously paid:
     
  (2) Form, Schedule or Registration Statement No.;
     
  (3) Filing Party:
     
  (4) Date Filed:

 

 
 

  

*** Exercise Your Right to Vote ***
Important Notice Regarding the Availability of Proxy Materials for the
Shareholder Meeting to Be Held on June 02, 2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NATUS MEDICAL INCORPORATED

 

Meeting Information

 

 

 

  Meeting Type:  Annual Meeting

 

 

 

  For holders as of:  April 08, 2016

 

 

 

  Date:  June 02, 2016         Time:  8:00 AM PDT

 




        




NATUS MEDICAL INCORPORATED
6701 Koll Center Parkway Suite 120
Plesanton, CA 94566
ATTN: Jonathan A. Kennedy


 

  Location: 

Natus Medical Incorporated
6701 Koll Center Parkway
Suite 120
Pleasanton, CA, 94566


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

You are receiving this communication because you hold shares in the above named company.
 
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

 

 

 

 

 

See the reverse side of this notice to obtain proxy materials and voting instructions.

 

 

0000283376_1      R1.0.1.25

 
 

 

    Before You Vote    
       

How to Access the Proxy Materials 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proxy Materials Available to VIEW or RECEIVE:

 

 

 

 

 

 

1. Notice & Proxy Statement          2. Annual Report

 

       

 

 

How to View Online:

 

 

 

Have the information that is printed in the box marked by the arrow (GRAPHIC) (located on the following page) and visit: www.proxyvote.com.

 

       

 

 

How to Request and Receive a PAPER or E-MAIL Copy:

 

 

 

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

 

 

 

 

 

1)

BY INTERNET:

www.proxyvote.com

 

 

 

 

 

2)

BY TELEPHONE:

1-800-579-1639

 

 

 

 

 

3)

BY E-MAIL*:

sendmaterial@proxyvote.com

 

 

 

*       If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow (GRAPHIC) (located on the following page) in the subject line.

 

 

 

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before May 19, 2016 to facilitate timely delivery.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    How To Vote    
       

Please Choose One of the Following Voting Methods 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 

 

 

 

 

 

 

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow (GRAPHIC) available and follow the instructions.

 

 

 

 

 

 

 

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

 

 

 

 

 

 

 

 

 

0000283376_2      R1.0.1.25

 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Voting items

 

 

 

 

 

 

 

         
The Board of Directors recommends you vote FOR the following:

 

 

 

 

 

 

 

 

 

 

 

 

 

1.

To elect two directors to serve for a term of three years;

 

 

 

 

 

                   

 

Nominees

 

 

 

 

 

 

 

 

                   

1a.

James B. Hawkins

                   
1b.

Robert A. Gunst

               

 

 

 

 

 

 

 

 

 

 

The Board of Directors recommends you vote FOR proposals 2 and 3.

 

 

 

 

 

 

 

 

 

 

2

To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2016;

 

 

       
3 Advisory approval of the Company’s named executive officer compensation;    
       
NOTE:  Transaction of such other business as may properly come before the meeting or any adjournment thereof.    
       

0000283376_3      R1.0.1.25